All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityEquity IPOs

Pharnext completes Paris IPO, raising €30.9m to fund advanced clinical trials

Pharnext, a French biopharmaceutical company specialising n treatments for neurological conditions such as Alzheimer’s disease, has successfully completed its IPO on the Alternext market of Euronext Paris.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree